To elucidate the bioactivities of sulindac and the underlying mechanism, the current study analyzed the efficacy of sulindac with regard to dosage as well as the involvement and roles of JNK1/β-catenin signaling in prostate cancer. The gene discussed is MAPK8; the disease is prostate carcinoma.